Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Kazuo Yashima
 -- 1924 2022-10-02 00:04:11 |
2 format
Jason Zhu
 Meta information modification 1924 2022-10-08 09:17:21 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Yashima, K.;  Shabana, M.;  Kurumi, H.;  Kawaguchi, K.;  Isomoto, H. Gastric Cancer Screening in Japan. Encyclopedia. Available online: https://encyclopedia.pub/entry/28201 (accessed on 02 July 2024).
Yashima K,  Shabana M,  Kurumi H,  Kawaguchi K,  Isomoto H. Gastric Cancer Screening in Japan. Encyclopedia. Available at: https://encyclopedia.pub/entry/28201. Accessed July 02, 2024.
Yashima, Kazuo, Michiko Shabana, Hiroki Kurumi, Koichiro Kawaguchi, Hajime Isomoto. "Gastric Cancer Screening in Japan" Encyclopedia, https://encyclopedia.pub/entry/28201 (accessed July 02, 2024).
Yashima, K.,  Shabana, M.,  Kurumi, H.,  Kawaguchi, K., & Isomoto, H. (2022, October 02). Gastric Cancer Screening in Japan. In Encyclopedia. https://encyclopedia.pub/entry/28201
Yashima, Kazuo, et al. "Gastric Cancer Screening in Japan." Encyclopedia. Web. 02 October, 2022.
Gastric Cancer Screening in Japan
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11154337

Gastric cancer is the second leading cause of cancer incidence in Japan, although gastric cancer mortality has decreased over the past few decades. This decrease is attributed to a decline in the prevalence of H. pylori infection. Radiographic examination has long been performed as the only method of gastric screening with evidence of reduction in mortality in the past. The revised 2014 Japanese Guidelines for Gastric Cancer Screening approved gastric endoscopy for use in population-based screening, together with radiography. While endoscopic gastric cancer screening has begun, there are some problems associated with its implementation, including endoscopic capacity, equal access, and cost-effectiveness. As H. pylori infection and atrophic gastritis are well-known risk factors for gastric cancer, a different screening method might be considered, depending on its association with the individual’s background and gastric cancer risk.

gastric cancer gastric cancer screening endoscopy

1. Introduction

Gastric cancer is the fifth most common cancer and the fourth leading cause of cancer-related deaths worldwide [1]. Helicobacter pylori (H. pylori) infection is considered the main cause of gastric cancer [2][3]. In Japan, the adjusted incidence and mortality rates of gastric cancer have decreased over the past few decades [4]. This decrease is mainly attributed to the reduction in H. pylori infection rates and the preventative effects of the H. pylori eradication therapy [5][6][7][8][9][10]. Despite this reduction, the number of gastric cancer cases ranks second and the number of deaths caused by gastric cancer ranks third in Japan [11], making it a critical public health problem.
In Japan, radiographic examination has been conducted since the 1960s as a secondary preventive measure for gastric cancer [12]. The revised 2014 Japanese Guidelines for Gastric Cancer Screening approved gastric endoscopy for use in population-based screening, together with radiography [13]. Currently, the government of Japan recommends either radiography or gastroscopic examination for gastric cancer screening [14]. However, there are some barriers, such as participation rate, endoscopic capacity, equal access, and cost-effectiveness [15][16][17][18].
Over 99% of gastric cancers in Japan are predisposed by a current or past H. pylori infection [19][20]. Furthermore, the background of gastric cancer risk has changed compared to the past due to the rapid decrease in the infection rate of H. pylori [5][6][7][8][9][10]. It has become necessary for efficient gastric cancer screening to classify patients as H. pylori-infected [8][21][22].

2. Gastric Cancer in Japan

2.1. Epidemiology of Gastric Cancer

In Japan, gastric cancer accounted for almost half of all cancer deaths in the 1960s, but the proportion continues to decline. According to the 2021 cancer statistics forecast of the National Cancer Center Cancer-Information Service, “Cancer Registration and Statistics”, gastric cancer ranked third in the number of deaths after lung cancer and colorectal cancer. The total number of cancer deaths was 11.1% (42,000 people) [11]. The number of gastric cancer deaths has remained at 50,000 per year for the past few decades, and since 2011, it has been declining. However, more than 40,000 people lose their lives to stomach cancer every year. Gastric cancer has the second highest incidence rate at 12.9% (130,500 people), following colorectal cancer. As for the annual transition of gastric cancer, the age-standardized incidence and mortality are steadily decreasing, the number of cases is increasing, and the number of deaths tends to plateau due to an increase in the incidence and deaths caused by gastric cancer in the elderly population.

2. H. pylori and Gastric Cancer

The International Agency for Research on Cancer designated H. pylori as a clear gastric cancer carcinogenic factor (group 1) in 1994 [23] and recommended prevention by eradication in 2014 [24]. The presence of H. pylori infection is determined by histologic examination, the rapid urease test, serum antibody test, stool antigen test, or 13C-urea breath test. The effectiveness of the eradication treatment on gastric cancer prevention has been shown in a randomized controlled trial [25], and this primary preventive effect of the eradication of gastric cancer has been reported in recent meta-analyses [26][27][28]. Eradication of H. pylori reduces the risk of gastric cancer and mortality [29][30][31][32], but the risk still remains in the second decade after eradication [33]. Moreover, the pathogenicity and carcinogenicity of H. pylori depend on its strain. The East Asian type of H. pylori, which is popular in Japan, is more carcinogenic than the European-type H. pylori [34][35]. In addition, the presence of H. pylori with a positive babA2 gene may contribute to an increased risk of GC, especially in the Asian population [35][36]. In Japan, the eradication treatment for gastric and duodenal ulcers was covered by the National Health Insurance in 2000, and H. pylori-infected gastritis was added as an indication in 2013 [37]. According to recent reports in Japan, the risk of cumulative incidence of gastric cancer was 17.0% in men and 7.7% in women in the H. pylori-infected population, and <1% in the non-infected population [38]. More than 99% of gastric cancers in Japan are associated with H. pylori-infection gastritis [19][20]. Histopathological diagnosis of gastric cancer is performed according to the Japanese Classification of Gastric Carcinoma and the Vienna classification system [39][40]. Although gastric cancer that is not associated with H. pylori infection is extremely rare, gastric is cancer associated with autoimmune gastritis, gastric cancer due to CDH1 gene mutation, fundic gland-type cancer, signet ring cell carcinoma, and cardia cancer are known [41]. Cardia cancer is often discovered at an advanced stage; thus, particular attention should be paid to it [42]. Moreover, the main risk factors of cardia cancer, which include gastroesophageal reflux disease and obesity, are different from those of gastric cancer associated with H. pylori [43].
As mentioned above, in Japan, the age-standardized incidence and mortality rate of gastric cancer has decreased over the past few decades due to a decrease in the incidence of H. pylori infection [4][5][6][7][8][9][10][11][12][13][14][15]. H. pylori infection rates in the 1960s, 1970s, and 1980s or later were 30%, 20%, and <10%, respectively [7]. A meta-analysis of the Japanese population shows that H. pylori infection rate is high in patients born in the 1940s; however, the infection rate decreased in patients who were born later, in the 1950s [9]. Although the morbidity rate of gastric cancer has continued to decrease due to the reduced H. pylori infection rates and the preventative effect of the H. pylori eradication therapy, the prevalence of H. pylori eradication has increased remarkably in recent years [8]. In the midst of dynamic changes in the incidence of H. pylori infection, it is considered to be important to pay attention to the high-risk groups in gastric cancer screening.

3. Gastric Cancer Screening Methods Used in Japan

3.1. Current Status and Problems of Upper Gastrointestinal Series

Annual radiographic screening for everyone >40 years of age in Japan was implemented in the 1960s as a secondary preventive measure for gastric cancer [12][14]. Gastric cancer screening using radiographic examination has proven to reduce mortality. It has an excellent mass-processing ability, and good accuracy, and is safe and cost-effective [44][45]. Furthermore, in recent case-control studies in Japan and South Korea, the effect of radiographic screening on mortality reduction was limited [46][47]. The Japan Society of Gastroenterological Cancer Screening formulated a revised version of the new gastric radiography guidelines (2011) [48]. The ability to view lesions by gastric radiographic examination has been greatly improved with the use of high-concentration, low-viscosity barium preparations and the advent of digital X-ray devices. Consequently, the rate of early detection of gastric cancer has exceeded 70% [49]. In addition, gastric cancer screening has been performed using imaging and AI to detect H. pylori-infected gastritis and gastric mucosal atrophy [50]. However, due to aging and immobilization of patients, radiation exposure, and lack of reading physicians and aging facilities, the rate of participation has been sluggish. Although endoscopic examinations have been approved by the revised 2014 Japanese Guidelines for Gastric Cancer Screening [13], it is impossible to replace all conventional radiography with endoscopic examinations due to problems relating to the capacity of endoscopy, budget, and access to examinees [14][15]. In population-based gastric cancer screening, it will be necessary to continue to utilize radiographic examinations with high processing capacity as a safety net.

3.2. Current Status and Problems of Upper Gastrointestinal Endoscopy

Radiographic examination is a screening method limited to Japan, but there is a growing international interest in endoscopic screening [51]. In Korea, in response to the results of domestic research, gastric cancer screening has been limited to endoscopic examinations [51][52].
In 2013, a case-control study was conducted in Japan and Korea. The research conducted in Japan involved a study on the population of Goto Islands in Nagasaki Prefecture [53] and a study on the population of Tottori Prefecture and Niigata City [54]. Although the sample size is small in the Nagasaki study, the mortality rate of gastric cancer was significantly decreased by 79% in participants of endoscopic screening (odds ratio [OR]: 0.206, 95% confidence interval [CI]: 0.044–0.965) [53]. In 2013, a case-control study that was conducted in Niigata City and four cities in Tottori Prefecture reported that the mortality rate was significantly lower by approximately 30% in people who underwent endoscopy 36 months before the date of gastric cancer diagnosis (OR: 0.695, 95% CI: 0.489–0.986) [54]. The studies that were conducted in Korea were large-scale research based on national databases. When the gastroscopic examination was performed even once in the past, the effect of reducing the gastric cancer mortality rate was confirmed to be 47% in individuals aged 40–74 years old (OR: 0.53, 95% CI: 0.51–0.56) [52]. Based on these results, a gastroscopy was recommended as a population-based screening method according to the revised 2014 Japanese Guidelines for Gastric Cancer Screening [13]. At the same time, it has changed from once a year for individuals aged >40 to once every 2 years for individuals aged >50 years, reflecting the recent decline in gastric cancer mortality by age group. In 2015, a study of Tottori Prefecture showed that endoscopic screening reduced the gastric cancer mortality rate by 67% compared with radiographic screening [46]. Zhang et al. conducted a meta-analysis that included 342,013 individuals in the six-cohorts and four-case-control studies that were previously published. This analysis demonstrated that endoscopic examination showed a 40% reduction in gastric cancer mortality rate (relative risk: 0.60, 95% CI: 0.49–0.73) [55].
According to reports from the area where endoscopic examinations were introduced, the gastric cancer detection rate was 0.05–0.32% for gastric X-ray examination and 0.30–0.87% for gastroscopic examinations [8][56]. Further, the gastric cancer detection rate of endoscopy was reported to have been approximately three times higher than that of X-ray examination. In Japanese studies, the proportion of early-stage cancer was approximately 70% in the radiographic screening group and >80% in the endoscopic screening group. Similarly, Hosokawa et al. previously reported that the detection rate of early cancer was higher in the endoscopic screening group than in the radiographic screening group [57]. However, the effectiveness of gastric cancer screening should be evaluated by the mortality reduction, and not by the detection rate.
Endoscopy can diagnose early-stage cancers that can be treated by endoscopic surgical dissection. Endoscopic surgical dissection has been performed for approximately half of early-stage cancers detected by endoscopic screening [58]. It seems to contribute to the maintenance of the quality of life after treatment. Moreover, recent development and widespread use of IEE and magnifying endoscopy have improved the endoscopic diagnosis of gastric cancer [59]. IEE is useful for diagnosing gastric cancer after eradication, which is usually difficult to detect [60]. In a recent study, researchers showed that photodynamic endoscopic diagnosis—based on the fluorescence of photosensitizers that accumulate in tumors—may be useful in the diagnosis of early gastric cancer regardless of the endoscopist’s experience and is useful for tumor detection; however, its usefulness has not been established because no prospective studies evaluating its usefulness have been performed [61].
As the participation rate in gastric cancer screening has decreased, its impact on mortality reduction has become limited. Although the participation rate in radiographic screening for gastric cancer has sunk below 10% [62], it is possible to improve the participation rate by introducing endoscopic screening as a method of gastric cancer screening. Notably, the participation rate is approximately 25% in municipalities that have already undergone endoscopic screening [63][64]. Thus, endoscopy is now the first choice for gastrointestinal tract examination instead of X-ray examination.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249.
  2. Schistosomes, liver flukes and Helicobacter pylori. International Agency for Research on Cancer monographs on the evaluation of carcinogenesis risks to humans. IARC Monogr. Eval. Carcinog. Risks Hum. 1994, 61, 208–220.
  3. Uemura, N.; Okamoto, S.; Yamamoto, S.; Matsumura, N.; Yamaguchi, S.; Yamakido, M.; Taniyama, K.; Sasaki, N.; Schlemper, R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345, 784–789.
  4. Katanoda, K.; Hori, M.; Saito, E.; Shibata, A.; Ito, Y.; Minami, T.; Ikeda, S.; Suzuki, T.; Matsuda, T. Updated trends in cancer in Japan: Incidence in 1985–2015 and mortality in 1958–2018—A sign of decrease in cancer incidence. J. Epidemiol. 2021, 31, 426–450.
  5. Kobayashi, T.; Kikuchi, S.; Lin, Y.; Yagyu, K.; Obata, Y.; Ogihara, A.; Hasegawa, A.; Miki, K.; Kaneko, E.; Mizukoshi, H.; et al. Trends in the incidence of gastric cancer in Japan and their associations with Helicobacter pylori infection and gastric mucosal atrophy. Gastric Cancer 2004, 7, 233–239.
  6. Ueda, J.; Gosho, M.; Inui, Y.; Matsuda, T.; Sakakibara, M.; Mabe, K.; Nakajima, S.; Shimoyama, T.; Yasuda, M.; Kawai, T.; et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter 2014, 19, 105–110.
  7. Kamada, T.; Haruma, K.; Ito, M.; Inoue, K.; Manabe, N.; Matsumoto, H.; Kusunoki, H.; Hata, J.; Yoshihara, M.; Sumii, K.; et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter 2015, 20, 192–198.
  8. Sugano, K. Screening of gastric cancer in Asia. Best Pract. Res. Clin. Gastroenterol. 2015, 29, 895–905.
  9. Wang, C.; Nishiyama, T.; Kikuchi, S.; Inoue, M.; Sawada, N.; Tsugane, S.; Lin, Y. Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): A systematic review and meta-regression analysis of 170,752 individuals. Sci. Rep. 2017, 7, 15491.
  10. Lin, Y.; Kawai, S.; Sasakabe, T.; Nagata, C.; Naito, M.; Tanaka, K.; Sugawara, Y.; Mizoue, T.; Sawada, N.; Matsuo, K. Effects of Helicobacter pylori eradication on gastric cancer incidence in the Japanese population: A systematic evidence review. Jpn. J. Clin. Oncol. 2021, 51, 1158–1170.
  11. National Cancer Center. Center for Cancer Control and Information Services. 2021. Available online: https://ganjoho.jp/public/index.html (accessed on 1 January 2022).
  12. Oshima, A. A critical review of cancer screening programs in Japan. Int. J. Technol. Assess. Health Care 1994, 10, 346–358.
  13. Hamashima, C. Systematic review group and guideline development group for gastric cancer screening guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn. J. Clin. Oncol. 2018, 48, 673–683.
  14. Hamashima, C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan. Jpn. J. Clin. Oncol. 2018, 48, 278–286.
  15. Hamashima, C.; Goto, R. Potential capacity of endoscopic screening for gastric cancer in Japan. Cancer Sci. 2017, 108, 101–107.
  16. Hamashima, C. Overdiagnosis of gastric cancer by endoscopic screening. World J. Gastrointest. Endosc. 2017, 9, 55–60.
  17. Hamashima, C.; Yoshimura, K.; Fukao, A. A study protocol for expanding the screening interval of endoscopic screening for gastric cancer based on individual risks: Prospective cohort study of gastric cancer screening. Ann. Transl. Med. 2020, 8, 1604.
  18. Mabe, K.; Inoue, K.; Kamada, T.; Kato, K.; Kato, M.; Haruma, K. Endoscopic screening for gastric cancer in Japan: Current status and future perspectives. Dig. Endosc. 2022, 34, 412–419.
  19. Matsuo, T.; Ito, M.; Takata, S.; Tanaka, S.; Yoshihara, M.; Chayama, K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011, 16, 415–419.
  20. Ono, S.; Kato, M.; Suzuki, M.; Ishigaki, S.; Takahashi, M.; Haneda, M.; Mabe, K.; Shimizu, Y. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 2012, 86, 59–65.
  21. Mizota, Y.; Yamamoto, S. How long should we continue gastric cancer screening? From an epidemiological point of view. Gastric Cancer 2019, 22, 456–462.
  22. Kishikawa, H. The clinical benefits, limitations, and perspectives of the ABC method. Intern. Med. 2020, 59, 1471–1472.
  23. Park, J.Y.; Greenberg, E.R.; Parsonnnet, J.; Wild, C.P.; Forman, D.; Herrero, R. Summary of IARC Working Group Meeting on Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer; IARC Working Group Report 8; International Agency for Research on Cancer: Lyon, France, 2014; pp. 1–4.
  24. Greenberg, E.R.; Park, J.Y. Effectiveness of Helicobacter pylori eradication. In Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer; IARC Working Group Report 8; International Agency for Research on Cancer: Lyon, France, 2014; pp. 64–71.
  25. Li, W.Q.; Ma, J.L.; Zhang, L.; Brown, L.M.; Li, J.Y.; Shen, L.; Pan, K.F.; Liu, W.D.; Hu, Y.; Han, Z.X.; et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J. Natl. Cancer Inst. 2014, 106, dju116.
  26. Lee, Y.C.; Chiang, T.H.; Chou, C.K.; Tu, Y.K.; Liao, W.C.; Wu, M.S.; Graham, D.Y. Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology 2016, 150, 1113–1124.e5.
  27. Sugano, K. Effect of helicobacter pylori eradication on the incidence of gastric cancer: A systematic review and meta-analysis. Gastric Cancer 2019, 22, 435–445.
  28. Ford, A.C.; Yuan, Y.; Moayyedi, P. Helicobacter pylori eradication therapy to prevent gastric cancer: Systematic review and metaanalysis. Gut 2020, 69, 2113–2121.
  29. Fukase, K.; Kato, M.; Kikuchi, S.; Inoue, K.; Uemura, N.; Okamoto, S.; Terao, S.; Amagai, K.; Hayashi, S.; Asaka, M.; et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An openlabel, randomised controlled trial. Lancet 2008, 372, 392–397.
  30. Li, W.Q.; Zhang, J.Y.; Ma, J.L.; Li, Z.X.; Zhang, L.; Zhang, Y.; Guo, Y.; Zhou, T.; Li, J.Y.; Shen, L.; et al. Effects of helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: Follow-up of a randomized intervention trial. BMJ 2019, 366, l5016.
  31. Choi, I.J.; Kim, C.G.; Lee, J.Y.; Kim, Y.I.; Kook, M.C.; Park, B.; Joo, J. Family History of Gastric Cancer and Helicobacter pylori Treatment. N. Engl. J. Med. 2020, 382, 427–436.
  32. Chiang, T.; Chang, W.; Chen, S.L.; Yen, A.M.; Fann, J.C.; Chiu, S.Y.; Chen, Y.R.; Chuang, S.L.; Shieh, C.F.; Liu, C.Y.; et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands. Gut 2021, 70, 243–250.
  33. Take, S.; Mizuno, M.; Ishiki, K.; Kusumoto, C.; Imada, T.; Hamada, F.; Yoshida, T.; Yokota, K.; Mitsuhashi, T.; Okada, H. Risk of gastric cancer in the second decade of follow-up after helicobacter pylori eradication. J. Gastroenterol. 2020, 55, 281–288.
  34. Satomi, S.; Yamakawa, A.; Matsunaga, S.; Masaki, R.; Inagaki, T.; Okuda, T.; Suto, H.; Ito, Y.; Yamazaki, Y.; Kuriyama, M.; et al. Relationship between the diversity of the cagA gene of Helicobacter pylori and gastric cancer in Okinawa, Japan. J. Gastroenterol. 2006, 41, 668–673.
  35. Yamaoka, Y.; Kato, M.; Asaka, M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern. Med. 2008, 47, 1077–1083.
  36. Kpoghomou, M.A.; Wang, J.; Wang, T.; Jin, G. Association of Helicobacter pylori babA2 gene and gastric cancer risk: A meta-analysis. BMC Cancer 2020, 20, 465.
  37. Asaka, M.; Mabe, K. Strategies for eliminating death from gastric cancer in Japan. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2014, 90, 251–258.
  38. Kawai, S.; Wang, C.; Lin, Y.; Sasakabe, T.; Okuda, M.; Kikuchi, S. Lifetime incidence risk for gastric cancer in the Helicobacter pylori-infected and uninfected population in Japan: A Monte Carlo simulation study. Int. J. Cancer 2022, 150, 18–27.
  39. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-3rd English edition. Gastric Cancer 2011, 14, 101–112.
  40. Schlemper, R.J.; Riddell, R.H.; Kato, Y.; Borchard, F.; Cooper, H.S.; Dawsey, S.M.; Dixon, M.F.; Fenoglio-Preiser, C.M.; Fléjou, J.F.; Geboes, K.; et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000, 47, 251–255.
  41. Yamamoto, Y.; Fujisaki, J.; Omae, M.; Hirasawa, T.; Igarashi, M. Helicobacter pylori-negative gastric cancer: Characteristics and endoscopic findings. Dig. Endosc. 2015, 27, 551–561.
  42. Imamura, Y.; Watanabe, M.; Oki, E.; Morita, M.; Baba, H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann. Gastroenterol. Surg. 2020, 5, 46–59.
  43. Crew, K.D.; Neugut, A.I. Epidemiology of gastric cancer. World J. Gastroenterol. 2006, 12, 354–362.
  44. Ohshima, A.; Hirata, N.; Ubukata, T.; Umeda, K.; Fujimoto, I. Evaluation of a mass screening program for stomach with a case control study design. Int. J. Cancer 1986, 38, 829–833.
  45. Fukao, A.; Tsubono, Y.; Tsuji, I.; Hisamichi, S.; Sugahara, N.; Takano, A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: A population-based case-control study. Int. J. Cancer 1995, 60, 45–48.
  46. Hamashima, C.; Shabana, M.; Okada, K.; Okamoto, M.; Osaki, Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015, 106, 1744–1749.
  47. Jun, J.K.; Choi, K.S.; Lee, H.Y.; Suh, M.; Park, B.; Song, S.H.; Jung, K.W.; Lee, C.W.; Choi, I.J.; Park, E.C.; et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology 2017, 152, 1319–1328.e7.
  48. The Japanese Society of Gastrointestinal Cancer Screening. New Guidelines of Radiography for Gastric Cancer Screening. 2011. Available online: https://www.jsgcs.or.jp (accessed on 14 December 2020).
  49. The Japanese Society of Gastrointestinal Cancer Screening. Annual Report of Gastrointestinal Cancer Screening 2014. Available online: https://www.jsgcs.or.jp (accessed on 14 December 2020).
  50. Togo, R.; Yamamichi, N.; Mabe, K.; Takahashi, Y.; Takeuchi, C.; Kato, M.; Sakamoto, N.; Ishihara, K.; Ogawa, T.; Haseyama, M. Detection of gastritis by a deep convolutional neural network from double-contrast upper gastrointestinal barium x-ray radiography. J. Gastroenterol. 2019, 54, 321–329.
  51. Choi, K.S.; Jun, J.K.; Suh, M.; Park, B.; Noh, D.K.; Song, S.H.; Jung, K.W.; Lee, H.Y.; Choi, I.J.; Park, E.C. Effect of endoscopy screening on stage at gastric cancer diagnosis: Results of the National Cancer Screening Programme in Korea. Br. J. Cancer 2015, 112, 608–612.
  52. Choi, K.S.; Jun, J.K.; Park, E.C.; Park, S.; Jung, K.W.; Han, M.A.; Choi, I.J.; Lee, H.Y. Performance of different gastric cancer screening methods in Korea: A population-based study. PLoS ONE 2012, 7, e50041.
  53. Matsumoto, S.; Yoshida, Y. Efficacy of endoscopic screening in an isolated island: A case-control study. Indian J. Gastroenterol. 2014, 33, 46–49.
  54. Hamashima, C.; Ogoshi, K.; Okamoto, M.; Shabana, M.; Kishimoto, T.; Fukao, A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS ONE 2013, 8, e79088.
  55. Zhang, X.; Li, M.; Chen, S.; Hu, J.; Guo, Q.; Liu, R.; Zheng, H.; Jin, Z.; Yuan, Y.; Xi, Y.; et al. Endoscopic Screening in Asian Countries Is Associated With Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review. Gastroenterology 2018, 155, 347–354.e9.
  56. The Japanese Society of Gastrointestinal Cancer Screening. Quality Assurance Manual of Endoscopic Screening for Gastric Cancer in Japanese Communities. Jpn. J. Clin. Oncol. 2016, 46, 1053–1061. (In Japanese)
  57. Hosokawa, O.; Shinbo, T.; Matsuda, K.; Miyanaga, T. Impact of opportunistic endoscopic screening on the decrease of mortality from gastric cancer. J. Gatsroenterol. Cancer Screen 2011, 49, 401–409. (In Japanese)
  58. Ogoshi, K.; Narisawa, R.; Kato, T.; Saito, S.; Funagoshi, K.; Kinameri, K. Evaluation of endoscopic screening for gastric cancer in Niigata City: The reduction of the mortality rate. J. Gatsroenterol. Cancer Screen 2009, 47, 531–541. (In Japanese)
  59. Yao, K.; Uedo, T.; Kamada, T.; Hirasawa, T.; Nagahama, T.; Yoshinaga, S.; Oka, M.; Inoue, K.; Mabe, K.; Yao, T.; et al. Guidelines for endoscopic diagnosis of early gastric cancer. Dig. Endosc. 2020, 32, 663–698.
  60. Shichijo, S.; Uedo, N.; Michida, T. Detection of Early Gastric Cancer after Helicobacter pylori Eradication. Digestion 2021, 2, 54–61.
  61. Kurumi, H.; Kanda, T.; Ikebuchi, Y.; Yoshida, A.; Kawaguchi, K.; Yashima, K.; Isomoto, H. Current Status of Photodynamic Diagnosis for Gastric Tumors. Diagnostics 2021, 11, 1967.
  62. Ministry of Health, Labour and Welfare. The Report of Health Promotion and Community Health 2013. Available online: http://www.e-stat.go.jp/SG1/estat/GL08020101.do?_-toGL08020101_&tstatCode=000001030884&requestSender=dsearch (accessed on 1 September 2015).
  63. Shabana, M.; Hamashima, C.; Nishida, M.; Miura, K.; Kishimoto, T. Current status and evaluation of endoscopic screening for gastric cancer. Jpn. J. Cancer Det. Diagn. 2010, 17, 229–235. (In Japanese)
  64. Kitagawa, S.; Miyagawa, K.; Iriguchi, Y. The report of gastroenterological screening in 2012. J. Gastroenterol. Cancer Screen 2015, 53, 60–86. (In Japanese)
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Health Care Sciences & Services
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Kazuo Yashima
,
Michiko Shabana
,
Hiroki Kurumi
,
Koichiro Kawaguchi
,
Hajime Isomoto
View Times: 779
Entry Collection: Gastrointestinal Disease
Revisions: 2 times (View History)
Update Date: 08 Oct 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback